Evommune CEO sells 7,438 shares under 10b5-1 plan

Evommune, Inc. director and President & CEO Luis C. Pena reported an open-market sale of 7,438 shares of common stock on June 22, 2026 at a weighted average price of $22.71 per share.

Rhea-AI Filing Summary

Evommune, Inc. director and President & CEO Luis C. Pena reported an open-market sale of 7,438 shares of common stock on June 22, 2026 at a weighted average price of $22.71 per share. The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 2, 2026, indicating they were scheduled in advance. Following this sale, Pena directly holds 630,458 shares of Evommune common stock, so the sale represents only a small portion of his overall stake.

Insider Trade Summary 10b5-1

Net Seller: 7,438 shares

Net Sell 1 txn

Insider Pena Luis C.

Role President & CEO

Sold 7,438 shs ($169K)

Type	Security	Shares	Price	Value
Sale	Common Stock	7,438	$22.71	$169K

Holdings After Transaction: Common Stock — 630,458 shares (Direct)

Footnotes (2)

1. F1. The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2026.
2. F2. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.50 to $22.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 7,438 shares Weighted average sale price: $22.71 per share Post-transaction holdings: 630,458 shares +2 more

5 metrics

Shares sold 7,438 shares Open-market sale on June 22, 2026

Weighted average sale price $22.71 per share Common stock sale by CEO

Post-transaction holdings 630,458 shares Shares directly held after sale

Price range of sales $22.50–$22.99 per share Multiple transactions within this range

Trading plan adoption date March 2, 2026 Rule 10b5-1 plan governing sales

Key Terms

Rule 10b5-1 trading plan, weighted average price, open-market sale, Form 4

4 terms

Rule 10b5-1 trading plan regulatory

"The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2026."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Evommune (EVMN) CEO Luis C. Pena report in this Form 4 filing?

Luis C. Pena reported selling 7,438 Evommune common shares. The open-market sale occurred on June 22, 2026 at a weighted average price of $22.71 per share, and was executed under a pre-arranged Rule 10b5-1 trading plan.

How many Evommune (EVMN) shares did the CEO sell and at what price?

The CEO sold 7,438 shares at a weighted average of $22.71. The filing notes the sale occurred in multiple trades at prices ranging from $22.50 to $22.99 per share, with the average price reported in the main transaction line.

How many Evommune (EVMN) shares does Luis C. Pena hold after this transaction?

After the sale, Luis C. Pena directly holds 630,458 shares. This remaining position, disclosed in the Form 4, shows that the 7,438 shares sold represent only a small fraction of his overall Evommune common stock holdings.

Was the Evommune (EVMN) CEO’s share sale under a Rule 10b5-1 trading plan?

Yes, the sale was executed under a Rule 10b5-1 trading plan. A footnote explains the transactions were made pursuant to a trading plan adopted by Luis C. Pena on March 2, 2026, indicating they were pre-scheduled rather than discretionary.

What price range did Evommune (EVMN) shares trade at in the CEO’s Form 4 sale?

The reported sales occurred between $22.50 and $22.99 per share. The Form 4 footnote states that the weighted average price was $22.71, with multiple individual transactions executed across that specified price range.

Is the Evommune (EVMN) CEO’s Form 4 transaction a buy or sell action?

The Form 4 reports a sell transaction by the CEO. The filing classifies it as an open-market sale of common stock, with 7,438 shares sold and no corresponding purchases or derivative exercises reported in this specific filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/24/2026 - 07:59 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pena Luis C.

(Last) (First) (Middle)

C/O EVOMMUNE, INC.

1891 PAGE MILL ROAD

(Street)

PALO ALTO CALIFORNIA 94304

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Evommune, Inc. [ EVMN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/22/2026		S(1)		7,438	D	$22.71(2)	630,458	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2026.

2. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.50 to $22.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Gregory S. Moss, Attorney-in-Fact	06/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)